Nektar Therapeutics Amortization
Nektar Therapeutics (NKTR) reported Amortization of $1.63 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2024-11-08
- Nektar Therapeutics amortization for the quarter ending 2023-12-31 was $1.00K.
- Nektar Therapeutics amortization for fiscal 2023 was $1.63M, a 22.71% decline from fiscal 2022.
- Nektar Therapeutics amortization for fiscal 2022 was $2.11M.
| Period end | Amortization 3 month | Amortization 7 month | Amortization 9 month | Amortization 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.63M 10-K · filed 2024-03-05 | ||
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $2.11M 10-K · filed 2023-02-28 | $2.11M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |